Eli Lilly and Company LILY34.SA Stock
Eli Lilly and Company Price Chart
Eli Lilly and Company LILY34.SA Financial and Trading Overview
Eli Lilly and Company stock price | 128.18 BRL |
Previous Close | 93.54 BRL |
Open | 0 BRL |
Bid | 92.7 BRL x 0 |
Ask | 95.95 BRL x 0 |
Day's Range | 0 - 0 BRL |
52 Week Range | 0 - 105.5 BRL |
Volume | 0 BRL |
Avg. Volume | 8.05K BRL |
Market Cap | 2.68T BRL |
Beta (5Y Monthly) | 0.331 |
PE Ratio (TTM) | 104.65556 |
EPS (TTM) | 0.99 BRL |
Forward Dividend & Yield | 0.72 (0.76%) |
Ex-Dividend Date | August 14, 2023 |
1y Target Est | N/A |
LILY34.SA Valuation Measures
Enterprise Value | 102.5B BRL |
Trailing P/E | 104.65556 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 83.63726 |
Price/Book (mrq) | 7.5490904 |
Enterprise Value/Revenue | 3.196 |
Enterprise Value/EBITDA | 9.058 |
Trading Information
Eli Lilly and Company Stock Price History
Beta (5Y Monthly) | 0.331 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 105.5 BRL |
52 Week Low | 0 BRL |
50-Day Moving Average | 97.24 BRL |
200-Day Moving Average | 80.52 BRL |
LILY34.SA Share Statistics
Avg. Volume (3 month) | 8.05K BRL |
Avg. Daily Volume (10-Days) | 9.47K BRL |
Shares Outstanding | 28.48B |
Float | 897.74M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.0040% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 4.37 |
Trailing Annual Dividend Yield | 4.67% |
5 Year Average Dividend Yield | 132.00% |
Payout Ratio | 0.78290004 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | September 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 15.55% |
Operating Margin (ttm) | 37.27% |
Gross Margin | 78.66% |
EBITDA Margin | 35.28% |
Management Effectiveness
Return on Assets (ttm) | 11.62% |
Return on Equity (ttm) | 46.46% |
Income Statement
Revenue (ttm) | 32.07B BRL |
Revenue Per Share (ttm) | 1.18 BRL |
Quarterly Revenue Growth (yoy) | 36.79% |
Gross Profit (ttm) | 21.91B BRL |
EBITDA | 11.32B BRL |
Net Income Avi to Common (ttm) | 4.99B BRL |
Diluted EPS (ttm) | 0.9 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.62B BRL |
Total Cash Per Share (mrq) | 2.92 BRL |
Total Debt (mrq) | 20.33B BRL |
Total Debt/Equity (mrq) | 179.81 BRL |
Current Ratio (mrq) | 1.046 |
Book Value Per Share (mrq) | 12.477 |
Cash Flow Statement
Operating Cash Flow (ttm) | 5.71B BRL |
Levered Free Cash Flow (ttm) | 3.9B BRL |
Profile of Eli Lilly and Company
Country | Brazil |
State | IN |
City | Indianapolis |
Address | Lilly Corporate Center |
ZIP | 46285 |
Phone | 317 276 2000 |
Website | https://www.lilly.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 39000 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Q&A For Eli Lilly and Company Stock
What is a current LILY34.SA stock price?
Eli Lilly and Company LILY34.SA stock price today per share is 128.18 BRL.
How to purchase Eli Lilly and Company stock?
You can buy LILY34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eli Lilly and Company?
The stock symbol or ticker of Eli Lilly and Company is LILY34.SA.
Which industry does the Eli Lilly and Company company belong to?
The Eli Lilly and Company industry is Drug Manufacturers-General.
How many shares does Eli Lilly and Company have in circulation?
The max supply of Eli Lilly and Company shares is 28.52B.
What is Eli Lilly and Company Price to Earnings Ratio (PE Ratio)?
Eli Lilly and Company PE Ratio is 129.47473000 now.
What was Eli Lilly and Company earnings per share over the trailing 12 months (TTM)?
Eli Lilly and Company EPS is 0.99 BRL over the trailing 12 months.
Which sector does the Eli Lilly and Company company belong to?
The Eli Lilly and Company sector is Healthcare.